Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Active, not recruiting · Phase 3 · NCT01886872
Conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
At a glance
- Research payments reported, 2025
- $7.6M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 547
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Bendamustine Hydrochloride (drug), Biospecimen Collection (procedure), Bone Marrow Aspiration (procedure), Bone Marrow Biopsy (procedure), Computed Tomography (procedure), Ibrutinib (drug), Laboratory Biomarker Analysis (other), Quality-of-Life Assessment (other), Rituximab (biological)
- Dates
- Started 2014-01-15; completion 2027-06-24
- Results posted
- Yes
This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping t…
From ClinicalTrials.gov, last updated 2026-10-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $7.6M in research payments for this study in 2025 (12 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Institute of Health $7.6M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.